SHPRH

Across TCGA pan-cancer cohorts, SHPRH Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated SHPRH data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher SHPRH Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SHPRH expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

ESCA, LIHC, and SARC are the cancer types where SHPRH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.051	0.536	<.001	18	view →
LIHC	DFS	Median	II,III,IV	0.063	0.429	<.001	18	view →
SARC	OS	Median	All	0.228	0.831	<.001	12	view →
LUAD	OS	Median	III,IV	0.004	0.665	<.001	12	view →
UCEC	OS	Median	All	0.955	0.861	.026	10	view →
LUSC	OS	Median	All	0.938	0.665	.015	7	view →
LGG	OS	Median	All	0.006	0.890	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
KIRP	OS	Median	All	0.181	0.704	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

SHPRH–ESCA (DFS)

Open the ESCA breakdown →